Clinical Pharmacology & Therapeutics · 2012 · 151 citations · 31 references
MedicineMolecular GeneticsPharmacologyGene ExpressionMolecular PharmacologyPharmacogeneticsCytochrome P450 EnzymesCytochrome P450-mediated MetabolismHepatic Drug MetabolismNuclear ReceptorsReceptor PolymorphismsCyp3a4 Genetic VariationCyp3a4 Variant EffectsCytochrome P450 3A4 MetabolismCytochrome P450 Genetic PolymorphismGlucocorticoid Receptor GeneticsPeroxisome Proliferator-activated Receptor GeneticsPeroxisome Proliferator-activated ReceptorsSingle-nucleotide Polymorphisms
Interindividual variability in cytochrome P450 3A4 (CYP3A4) is believed to be largely heritable; however, predictive genetic factors have remained scarce. Using a candidate-gene approach in a human liver bank, we identified single-nucleotide polymorphisms (SNPs) in the Ah-receptor nuclear translocator (ARNT), glucocorticoid receptor (GR), progesterone receptor membrane component 2 (PGRMC2), and peroxisome proliferator-activated receptor-α (PPARA) that are associated with CYP3A4 phenotype. Validation in atorvastatin-treated volunteers confirmed a decrease in atorvastatin-2-hydroxylation in carriers of PPARA SNP rs4253728. Homozygous carriers expressed significantly less PPAR-α protein in the liver. Moreover, shRNA-mediated PPARA gene knockdown in primary human hepatocytes decreased expression levels of the PPAR-α target ACOX1 and of CYP3A4 by more than 50%. In conclusion, this study identified novel genetic determinants of CYP3A4 that, together with nongenetic factors, explained 52, 55, and 33% of hepatic CYP3A4 mRNA, protein, and atorvastatin-2-hydroxylase activity, respectively. These findings have implications for variability in response to drug substrates of CYP3A4.
31
Sex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Renzo Wolbold, Kathrin Klein, Oliver Burk et al. · Hepatology · 2003 · 510 citations · Full text
Medicine, Pharmacology, Toxicology +13